CA-ULTRAVIOLET-DEVICES
Ultraviolet Devices, Inc. (UVDI), a global leader in UV-C surface disinfecting and indoor air quality products, today announced its first Italian hospital studies demonstrating the advanced effectiveness of the UVDI-360 Room Sanitizer will be presented at the 16th World Congress on Public Health 2020, taking place October 12 – 16, 2020. The novel research, conducted by Dr. Gabriele Messina, Associate Professor of Public Health, University of Siena, at the Rugani Hospital Monteriggioni in Siena, demonstrates the UVDI-360’s ability to inactivate pathogens in the hospital environment as part of varied cleaning protocols, in multiple high-risk locations and at different disinfecting cycle times.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005076/en/
Presentations from Dr. Messina and his Team at the University of Siena include:
(1) one poster sharing preliminary data of a cross-sectional study measuring overall pathogen reduction on high-touch surfaces in hospital rooms pre-and-post use of the UVDI-360 Room Sanitizer as a supplement to terminal cleaning. Preliminary findings conclude 83% of sites sampled had 0 CFU following the use of the UVDI-360 Room Sanitizer.
(2) a second poster sharing preliminary data of a cross-sectional study demonstrating overall pathogen reduction in operating rooms in six minutes with the UVDI-360 Room Sanitizer used in multiple protocols: with no manual cleaning, manual cleaning in-between operating room use and as a supplement to manual terminal cleaning.
(3) an oral presentation sharing research demonstrating 3-and-4-log reductions of Candida auris at 2.44 meters using the UVDI-360 Room Sanitizer.
(4) a third poster illustrating a simulation model of microbe distribution on surfaces to inform future UV-C testing.
Title:
Six ultraviolet minutes for cleaner operating theatres
Track:
Health Technology Assessment
Abstract: #
DJ-15
Title: Analytical approach for a better control of environmental contamination
Track:
Hospital hygiene (including AMR), healthcare-associated infections (HAI)
Abstract:
#DN-18
Title:
A simulation model of microbe overlapping for the correct estimation of UV-C device log-reduction
Track:
Healthcare Technology Assessment
Abstract: #
DJ-14
Oral Presentation:
Tuning a UV-C device to challenge new threats in the sanitization setting of healthcare facilities
Date and Time:
October 13th
, 12:15-13:15
Poster abstracts are accessible via the World Congress website, https://wcph2020.com/ . The poster presentations may be accessed through UVDI’s website following their presentation.
About UVDI
UVDI's Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. Founded in 1949 by Louis Veloz, UVDI designs and makes next-generation germicidal Ultraviolet light solutions in California applying over 70 years and three generations of family craftsmanship and care. The UVDI-360 Room Sanitizer is now used globally in over 25 countries in the world’s leading hospitals, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate the highest-risk pathogens. UVDI is proud to be a certified Minority Business Enterprise (MBE).
View source version on businesswire.com: https://www.businesswire.com/news/home/20201011005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference23.10.2025 15:00:00 CEST | Press release
- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly in younger people with cystic fibrosis - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year’s conference demonstrate that improvement in CFTR function, as measured by reduction in sweat chloride (SwCl), is associated with improved outcomes in people with cystic fibrosis (CF). ALYFTREK has shown greater reductions in sweat chloride compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor
Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 202523.10.2025 15:00:00 CEST | Press release
Boomi earns top rankings across product capability, validation, and customer experience in dual Buyers Guides from ISG Software Research Boomi™, the leader in AI-driven automation, today announced it has been named an Exemplary Vendor in both the ISG Buyers Guide™ for Data Integration and the ISG Buyers Guide™ for Master Data Management 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023515342/en/ Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 2025 In these independently published reports from ISG Software Research, a division of ISG (Information Services Group), Boomi was recognized as a Leader across multiple evaluation dimensions, including Product Experience, Capability, Customer Experience, and Validation. Customer Experience and Validation The ISG Buyers Guide™ assessments are widely used by enterprise technology buyers to evaluate market-leadin
CWAN and J.P. Morgan Asset Management Launch Automated Cash Management Solution for Hedge Funds23.10.2025 15:00:00 CEST | Press release
New integration connects Enfusion by CWAN and Morgan Money® to optimize yield, diversification, and liquidity control for hedge fund clients Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, and J.P. Morgan Asset Management today announced an integration that transforms how hedge funds manage cash. The solution links Enfusion by CWAN directly with the Morgan Money® trading platform, J.P. Morgan Asset Management’s short-term investment management solution, giving clients a single, automated workflow for investing and monitoring idle cash. Through this connection, hedge funds can now: Maximize idle cash by automatically investing in a diversified range of money market funds. Reduce concentration risk by spreading cash across multiple managers, custodians, and currencies. Improve liquidity visibility through real-time data and automated withdrawal and deposit capabilities. Eliminate manual treasury work, freeing teams to focus on trad
Foresight Launches the First Conversational AI Interface to Query Unified Private Market Data23.10.2025 14:07:00 CEST | Press release
From deal sourcing to portfolio management, Foresight is shaping the future of how the private market engages with data Foresight is ushering in the next generation of private market software by letting its customers use natural language to query their unified pre- and post-deal data. Today, the company announced new AI capabilities that will give customers the ability to ask questions within the Foresight platform as well as in ChatGPT, Claude, and Glean through its new model context protocol (MCP) server. Private market dealmakers will be able to prompt Foresight’s AI for lists of prospective companies, and anyone who makes post-deal decisions will be able to ask portfolio questions, model scenarios, and execute workflows in natural language on Foresight’s desktop or mobile interfaces. “The $15 trillion private market has run on data silos and Excel, which has created unnecessary opacity. Foresight unlocks the data and analytics that fund managers and financial institutions need by u
Adtran launches industry-first Galileo OSNMA authentication for Oscilloquartz timing solutions23.10.2025 14:00:00 CEST | Press release
News summary: GNSS timing underpins 5G, finance and data centers, yet spoofing and signal manipulation threaten accuracy, reliability and trust Adtran’s Oscilloquartz technology now supports Galileo OSNMA, a new authentication service that verifies GNSS signals First-to-market timing innovation boosts GNSS resilience, helps futureproof deployments and sets a new benchmark for timing security Adtran today announced support for Galileo’s Open Service Navigation Message Authentication (OSNMA) across its Oscilloquartz synchronization platforms, marking a major advance in GNSS security. OSNMA is the first GNSS authentication service designed for civilian use, and Adtran is the first in the timing industry to support it. By verifying that timing data originates from genuine Galileo satellites, OSNMA ensures authenticity and integrity at the point of reception. Available via firmware update for supported multi-band GNSS receivers, the new feature adds an extra layer of protection against spoo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom